Jounce Therapeutics to Participate in Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeutics in Cancer
20 avr. 2022 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
02 mars 2022 07h00 HE
|
Jounce Therapeutics, Inc.
- Continued execution on two proof-of-concept clinical trials for JTX-8064 and Vopratelimab, INNATE and SELECT, with clinical data on track for 2022 - - JTX-1484, a new antagonist antibody...
Jounce Therapeutics to Participate in Cowen & Co. 42nd Annual Health Care Conference
28 févr. 2022 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Wednesday, March 2, 2022
23 févr. 2022 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at Upcoming Investor Conferences in January
04 janv. 2022 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at Upcoming Investor Conferences in November
09 nov. 2021 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Third Quarter 2021 Financial Results
04 nov. 2021 07h00 HE
|
Jounce Therapeutics, Inc.
- Commenced enrollment in tumor-specific monotherapy and pimivalimab combination expansion cohorts of INNATE trial of JTX-8064 - - Ended the quarter with $249.0 million in cash, cash equivalents and...
Jounce Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021
28 oct. 2021 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors
07 oct. 2021 08h00 HE
|
Jounce Therapeutics, Inc.
- Enrollment initiated in tumor-specific monotherapy and pimivalimab combination expansion cohorts – - Monotherapy and pimivalimab combination dose escalation enrollment completed - CAMBRIDGE,...
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
15 sept. 2021 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...